E. Ohman J:Or Asset Management Ab Biomarin Pharmaceutical Inc Transaction History

E. Ohman J:Or Asset Management Ab

$3.92 Trillion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 05, 2024	SELL	$74.28 - $92.69 $616,524 - $769,327	-8,300 Closed	0 $0
Q3 2021 Apr 05, 2024	SELL	$74.77 - $85.47 $97,201 - $111,111	-1,300 Reduced 13.54%	8,300 $642 Million
Q4 2020 Apr 05, 2024	BUY	$72.61 - $90.2 $181,525 - $225,500	2,500 Added 35.21%	9,600 $842 Million
Q3 2020 Apr 05, 2024	SELL	$71.87 - $131.03 $18.6 Million - $33.8 Million	-258,137 Reduced 97.32%	7,100 $540 Million
Q2 2020 Apr 05, 2024	BUY	$79.55 - $124.22 $2.17 Million - $3.39 Million	27,317 Added 11.48%	265,237 $32.7 Billion

Q1 2020 Apr 05, 2024	BUY	$71.37 - $96.85 $1.96 Million - $2.66 Million	27,497 Added 13.07%	237,920 $20.1 Billion
Q4 2019 Apr 05, 2024	BUY	$64.27 - $86.37 $2.56 Million - $3.44 Million	39,830 Added 23.35%	210,423 $17.8 Billion
Q3 2019 Apr 05, 2024	BUY	$67.4 - $85.11 $11.2 Million - $14.2 Million	166,393 Added 3961.74%	170,593 $11.5 Billion
Q2 2019 Apr 05, 2024	SELL	$80.35 - $93.9 $329,435 - $384,990	-4,100 Reduced 49.4%	4,200 $360 Million
Q3 2018 Apr 05, 2024	BUY	$93.92 - $105.72 $75,136 - $84,576	800 Added 10.67%	8,300 $805 Million
Q2 2018 Apr 05, 2024	BUY	$76.01 - $99.03 $205,227 - $267,381	2,700 Added 56.25%	7,500 $707 Million
Q1 2018 Apr 05, 2024	SELL	$77.67 - $92.63 $93,204 - $111,156	-1,200 Reduced 20.0%	4,800 $389 Million
Q4 2017 Apr 05, 2024	BUY	$80.76 - $95.13 $72,684 - $85,617	900 Added 17.65%	6,000 $535 Million
Q3 2017 Apr 05, 2024	BUY	$80.6 - $94.95 $8,059 - $9,495	100 Added 2.0%	5,100 $475 Million
Q1 2017 Apr 05, 2024	BUY	N/A	1,700 Added 51.52%	5,000 $439 Million
Q2 2013 Apr 05, 2024	BUY	N/A	3,300	3,300 $184 Million

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.

Account